The potential of pharmacogenomics to treat drug addiction

Pharmacogenomics

Volumn 10, Issue 12, 2009, Pages 1883-1886

  Haile, Colin N ^a   Kosten, Thomas R ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BUPRENORPHINE; DEXAMPHETAMINE; DISULFIRAM; METHADONE; METHYLPHENIDATE; NALTREXONE; TOPIRAMATE; VARENICLINE;

ALCOHOLISM; AMINO ACID SUBSTITUTION; CLINICAL TRIAL; COCAINE DEPENDENCE; DRUG APPROVAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; EDITORIAL; FATIGUE; GENETIC VARIABILITY; HUMAN; HYPESTHESIA; METHADONE TREATMENT; NAUSEA; NICOTINE REPLACEMENT THERAPY; OPIATE ADDICTION; PARESTHESIA; PATIENT SELECTION; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PRESCRIPTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SOMNOLENCE; TOBACCO DEPENDENCE;

ALCOHOLISM; HUMANS; OPIOID-RELATED DISORDERS; PHARMACOGENETICS; TOBACCO USE DISORDER;

EID: 73649089686     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.146     Document Type: Editorial

References (50)

1. Frueh FW, Amur S, Mummaneni P et al.: Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28, 992-998 (2008).
2. de Leon J: The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J. Clin. Psychopharmacol. 27, 241-245 (2007).
3. deLeon J, Armstrong SC, Cozza KL: Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 and CYP450 2C19. Psychosomatics 47, 75-85 (2006).
4. Szegedi A, Rujescu D, Tadic A et al.: The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 5, 49-53 (2005).
5. Schosser A, Kasper S : The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int. Clin. Psychopharmacol. 24(6), 277-288 (2009).
6. Arranz MJ, de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 12, 707-747 (2007).
7. Opgen-Rhein C, Dettling M: Clozapine-induced agranulocytosis and its genetic determinants. Pharmacogenomics 9, 1101-1111 (2008).
8. de Leon J: The future (or lack of future) of personalized prescription in psychiatry. Pharmacol. Res. 59, 81-89 (2009).
9. Haile CN, Kosten TA, Kosten TR: Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am. J. Drug. Alcohol. Abuse 34, 355-381 (2008). Interesting review.
10. Haile CN, Kosten TR, Kosten TA: Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am. J. Drug. Alcohol. Abuse 35, 161-177 (2009). Interesting review.
11. Bond C, LaForge KS, Tian M et al.: Single-nucleotide polymorphism in the human μ opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95, 9608-9613 (1998).
12. Beyer A, Koch T, Schroder H, Schulz S, Hollt V: Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human μ-opioid receptor. J. Neurochem. 89, 553-560 (2004).
13. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ: The single nucleotide polymorphism A118G alters functional properties of the human μ opioid receptor. J. Neurochem. 103, 77-87 (2007).
14. Ray LA, Hutchison KE: A polymorphism of the μ-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin. Exp. Res. 28, 1789-1795 (2004). Discusses the basic findings for alcohol.
15. Ray LA, Hutchison KE: Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch. Gen. Psychiatry 64, 1069-1077 (2007).
16. Oslin DW, Berrettini WH, O'Brien CP: Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addict. Biol. 11, 397-403 (2006).
17. Anton RF, O'Malley SS, Ciraulo DA et al.: Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295, 2003-2017 (2006).
18. Oroszi G, Anton RF, O'Malley S et al.: OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin. Exp. Res. 33, 383-393 (2009).
19. Dodick DW, Freitag F, Banks J et al.: Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin. Ther. 31, 542-559 (2009).
20. Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR; Clinical Affairs Product Support Study-168 Investigators: Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J. Clin. Psychiatry 67, 1698-1706 (2006).
21. Johnson BA, Rosenthal N, Capece JA et al.: Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298, 1641-1651 (2007).
22. Johnson BA, Rosenthal N, Capece JA et al.: Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch. Intern. Med. 168, 1188-1199 (2008).
23. White HS, Smith MD, Wilcox KS: Mechanisms of action of antiepileptic drugs. Int. Rev. Neurobiol. 81, 85-110 (2007).
24. Ray LA, Miranda R Jr, MacKillop J et al.: A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp. Clin. Psychopharmacol. 17, 122-129 (2009).
25. Kosten TR, Kleber HD: Buprenorphine detoxification from opioid dependence: a pilot study. Life Sci. 42, 635-641 (1988).
26. Kosten TR, Morgan C, Kosten TA: Treatment of heroin addicts using buprenorphine. Am. J. Drug. Alcohol. Abuse 17, 119-128 (1991).
27. Kobayashi K, Yamamoto T, Chiba K et al.: Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab. Dispos. 26, 818-821 (1998).
28. Tyndale RF, Droll KP, Sellers EM: Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 7, 375-379 (1997). Discusses the basic findings for nicotine.
29. Crettol S, Déglon JJ, Besson J et al.: ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. 80, 668-681 (2006).
30. Volkow ND, Wang GJ, Fowler JS et al.: Relationship between psychostimulant-induced "high" and dopamine transporter occupancy. Proc. Natl Acad. Sci. USA 93, 10388-10392 (1996).
31. Volkow ND, Wang GJ, Fowler JS et al.: Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replications study. Synapse 46, 79-82 (2002).
32. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F: Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch. Neurol. 64, 1575-1579 (2007).
33. Wang GJ, Volkow ND, Fowler JS et al.: Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropharmacology 16, 174-182 (1997).
34. Crettol S, Besson J, Croquette-Krokar M et al.: Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1722-1727 (2008).
35. Gu DF, Hinks LJ, Morton NE, Day IN: The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann. Hum. Genet. 64, 383-390 (2000).
36. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF: Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol. Psychiatry 11, 400-409 (2006).
37. Fujieda M, Yamazaki H, Saito T et al.: Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25, 2451-2458 (2004).
38. Mills EJ, Wu P, Spurden D, Ebbert J, Wilson K: Efficacy of pharmacotherapies for short-term smoking abstinence: a systematic review and meta-analysis. Harm. Reduct. J. 6, 25 (2009).
39. Swan GE, Valdes AM, Ring HZ et al.: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J. 5, 21-29 (2005).
40. Carroll KM, Fenton LR, Ball SA et al.: Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch. Gen. Psychiatry 61, 264-272 (2004).
41. Carroll KM, Nich C, Ball SA et al.: One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 95, 1335-1349 (2000).
42. Rush CR, Stoops WW, Hays LR: Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend. 99, 261-271 (2009).
43. Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J: Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 98, 1137-1141 (2003).
44. Grabowski J, Rhoades H, Schmitz J et al.: Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol. 21, 522-526 (2001).
45. Grabowski J, Rhoades H, Stotts A et al.: Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 29, 969-981 (2004).
46. Tiihonen J, Kuoppasalmi K, Föhr J et al.: A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am. J. Psychiatry 164, 160-162 (2007).
47. Zabetian CP, Anderson GM, Buxbaum SG et al.: A quantitative-trait analysis of human plasma-dopamine β-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am. J. Genet. 68, 515-522 (2001).
48. Lott DC, Kim SJ, Cook EH, de Wit H: Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 30, 602-609 (2005).
49. Gruber R, Joober R, Grizenko N et al.: Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder. J. Child. Adolesc. Psychopharmacol. 19, 233-239 (2009).
50. Dlugos AM, Hamidovic A, Palmer AA, de Wit H: Further evidence of association between amphetamine response and SLC6A2 gene variants. Psychopharmacology (Berl.) 206, 501-511 (2009).